US health authority reprimands large pharmaceutical firms after disagreement on drug discounts

Earlier in the week, the US HRSA sent a letter to many of the largest companies in the pharmaceutical industry concerning their approach to the 340B program which aims to ensure that hospitals get drug discounts.
Photo: Mike Segar/Reuters/Ritzau Scanpix
Photo: Mike Segar/Reuters/Ritzau Scanpix

The US Department of Health & Human Services (HHS) is cracking down on many of the largest players in the pharmaceutical industry according to healthcare media Endpoints.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading